1
|
Xu Y, Chen H, Wang B, Zhu X, Luo L, Wang S, Xiao Y, Wang H, Ma R, Liu S, Yan L, Li X, Chen D, Su Y, Chai Y, Fu J, Mao X, Cao J, Sun P, Tang F, Sun X, Wang Z, Yang X. Immunogenicity and safety of concomitant administration of the sabin-strain-based inactivated poliovirus vaccine, the diphtheria-tetanus-acellular pertussis vaccine, and measles-mumps-rubella vaccine to healthy infants aged 18 months in China. Int J Infect Dis 2023; 137:9-15. [PMID: 37832931 DOI: 10.1016/j.ijid.2023.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Revised: 10/05/2023] [Accepted: 10/06/2023] [Indexed: 10/15/2023] Open
Abstract
OBJECTIVES During the COVID-19 pandemic, there was a decline in vaccine coverage, and the implementation of combined vaccines and co-administration strategies emerged as potential solutions to alleviate this predicament. Our objective is to delve into the concurrent administration of the sabin-strain-based inactivated poliovirus vaccine (sIPV), the diphtheria-tetanus-acellular pertussis vaccine (DTaP), and measles-mumps-rubella vaccine (MMR), with the intention of bridging the evidentiary gap pertaining to vaccine co-administration in Chinese infants, and to ensure a safe and effective vaccination strategy, ultimately leading to an augmentation in immunization coverage. METHODS This study was a follow-up trial of the "Immunogenicity and safety of concomitant administration of the sIPV with the DTaP vaccine in children: a multicenter, randomized, non-inferiority, controlled trial." Blood samples were collected on day 0 and day 30, and serum antibody levels were detected to measure antibody responses to each of the antigens. Local and systemic adverse events were monitored and compared among groups. This study is the first to fill the knowledge gap in China regarding the safe and effective combined vaccination of sIPV, DTaP, and MMR vaccines. RESULTS The geometric mean titer of the poliovirus types I, II, and III neutralizing antibodies were 1060.22 (95% CI: 865.73-1298.39), 1537.06 (95% CI: 1324.27-1784.05), and 1539.10 (95% CI: 1296.37-1827.29) in group I on day 30; geometric mean titer of antibodies against DTaP and MMR in the simultaneous vaccination group was non-inferior to those in the DTaP alone and MMR alone group. Reporting rates of local and systemic adverse reactions were similar between groups and no serious adverse events were reported throughout the clinical study period. CONCLUSION Co-administration of the sIPV, DTaP, and MMR was safe and did not impact immunogenicity, which would help to mitigate administrative costs and enhance vaccine coverage rates.
Collapse
Affiliation(s)
- Yan Xu
- Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Haiping Chen
- Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China
| | - Binbing Wang
- Expanded Program on Immunization, Anhui Provincial Center for Disease Control and Prevention, Hefei, China
| | - Xiaoping Zhu
- Vaccine research center, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China
| | - Linyun Luo
- Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China
| | - Shengyi Wang
- Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China
| | - Yanhui Xiao
- Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China
| | - Hui Wang
- Medical Affairs Department, Beijing Institute of Biological Products Company Limited, Beijing, China
| | - Rui Ma
- Medical Affairs Department, Beijing Institute of Biological Products Company Limited, Beijing, China
| | - Shaoxiang Liu
- Medical Affairs Department, Chengdu Institute of Biological Products Company Limited, Chengdu, China
| | - Long Yan
- Medical Affairs Department, Chengdu Institute of Biological Products Company Limited, Chengdu, China
| | - Xiuling Li
- Medical Affairs Department, Shanghai Institute of Biological Products Company Limited, Shanghai, China
| | - Dandan Chen
- Medical Affairs Department, Shanghai Institute of Biological Products Company Limited, Shanghai, China
| | - Ying Su
- Expanded Program on Immunization, Anhui Provincial Center for Disease Control and Prevention, Hefei, China
| | - Yu Chai
- Expanded Program on Immunization, Anhui Provincial Center for Disease Control and Prevention, Hefei, China
| | - Jun Fu
- Vaccine research center, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China
| | - Xiaoying Mao
- Vaccine research center, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China
| | - Jie Cao
- Expanded Program on Immunization, Jiangyou Center for Disease Control and Prevention, Mianyang, China
| | - Pufei Sun
- Expanded Program on Immunization, Jiangyou Center for Disease Control and Prevention, Mianyang, China
| | - Fenyang Tang
- Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Xiang Sun
- Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
| | - Zhiguo Wang
- Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Xiaoming Yang
- Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China
| |
Collapse
|
2
|
Chu K, Li Y, Yu D, Song Y, Liu S, Xue F, Shan Y, Meng W, Pan H. Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study. Vaccine 2023; 41:3467-3471. [PMID: 37127526 DOI: 10.1016/j.vaccine.2023.03.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Revised: 02/24/2023] [Accepted: 03/05/2023] [Indexed: 05/03/2023]
Abstract
BACKGROUND Sabin strain inactivated poliovirus vaccine (hereinafter as "sIPV") has been marketed globally in recent years, and more data on its immune persistence are needed. METHODS This is a phase IV, open-labeled, parallel-controlled observational study based on phase III clinical trial as required by the China National Medical Products Administration (NMPA). At least 450 subjects aged four years (48-54 months) who received four doses at 2, 3, 4 and 18 months of age of sIPV or wild strain poliovirus vaccine (wIPV) in phase III clinical trial enrolled at a 2:1 ratio and collected blood samples for neutralizing antibody testing. RESULTS A total of 500 subjects of four years old (334 in the sIPV group and 166 in wIPV group) were finally enrolled. The seropositivity rates (≥1:8) of neutralizing antibodies against serotype I-III were all 100.00% in all participants, and the geometric mean titers (GMT) were 1117.33 vs. 337.77 against serotype I, 632.72 vs. 267.34 against serotype Ⅱ, 1665.98 vs. 923.02 against serotype III in the sIPV group and wIPV group respectively at 4 years old. The seropositivity rates and GMTs of neutralizing antibodies in the test group were non-inferior to that of the control group against all three serotypes at different time points (P < 0.0001). The antibody GMT experienced a 10-fold, 8-fold, and 7-fold decline for serotypes I, Ⅱ, and III in the sIPV group, and a 13-fold, 7-fold, and 7-fold decline in the wIPV group from one month after booster vaccination to 4 years old. CONCLUSIONS The neutralizing antibody level is much higher than the seroprotection cutoff (≥1:8) among children of 4 years old who completed the four-dose vaccination of either sIPV or wIPV. Therefore, another booster vaccination is not recommended at 4 years old. Longer immune persistence observation is still ongoing. REGISTRATION ClinicalTrials.gov Identifier: NCT04989231.
Collapse
Affiliation(s)
- Kai Chu
- Institute of Clinical Evaluation of Vaccines, Jiangsu Provincial Center for Disease Control and Prevention. No. 172, Jiangsu Road, Nanjing, Jiangsu Province 210009, China.
| | - Yurong Li
- Clinical Research Department Center, Sinovac Life Science Co., Ltd. No. 21, Tianfu Street, Daxing Biomedicine Industrial Base, Zhongguancun Science Park, Daxing District, Beijing 102629, China.
| | - Dan Yu
- Quality Assurance Department, Sinovac Biotech Co., Ltd, No. 39, Shangdi West Road, Haidian District, Beijing 100085, China.
| | - Yufei Song
- Clinical Research Department Center, Sinovac Biotech Co., Ltd, No. 39, Shangdi West Road, Haidian District, Beijing 100085, China.
| | - Sheng Liu
- Project Office, Pizhou City Center for Disease Control and Prevention, No. 72, Fuzhou Road, Pizhou City, Xuzhou 221000, China.
| | - Feng Xue
- Novel Coronavirus Vaccine Department, Sinovac Life Science Co., Ltd. No. 21, Tianfu Street, Daxing Biomedicine Industrial Base, Zhongguancun Science Park, Daxing District, Beijing 102629, China.
| | - Yongmei Shan
- Medicine Outpatient Department, Guanyun County Center for Disease Control and Prevention Preventive, No.1, Xihuan North Road, Guanyun County, Lianyungang City, 222200, China.
| | - Weining Meng
- International Registration Department, Sinovac Life Science Co., Ltd. No. 21, Tianfu Street, Daxing Biomedicine Industrial Base, Zhongguancun Science Park, Daxing District, Beijing, 102629, China.
| | - Hongxing Pan
- Institute of Clinical Evaluation of Vaccines, Jiangsu Provincial Center for Disease Control and Prevention. No. 172, Jiangsu Road, Nanjing, Jiangsu Province, 210009, China.
| |
Collapse
|
3
|
Yu-Ping Z, Jing L, Teng H, Zhi-Fang Y, Ting Z, Yan-Chun C, Zhi-Mei Z, Yu-Ting F, Jun-Hui T, Qing-Hai Y, Ding-Kai W, Guo-Liang L, Xiao-Lei Y, Li Y, Hong-Bo C, Jian-Feng W, Rui-Ju J, Lei Y, Wei C, Wei Y, Ming-Xue X, Qiong-Zhou Y, Jing P, Li S, Chao H, Yan D, Lu-Kui C, Jian Z, Yu W, Hong-Sen L, Wei H, Zhao-Jun M, Chang-Gui L, Qi-Han L, Jing-Si Y. Evaluation of the immunization effectiveness of bOPV booster immunization and IPV revaccination. NPJ Vaccines 2023; 8:44. [PMID: 36934085 PMCID: PMC10024706 DOI: 10.1038/s41541-023-00642-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Accepted: 03/07/2023] [Indexed: 03/20/2023] Open
Abstract
To provide a basis for further optimization of the polio sequential immunization schedule, this study evaluated the effectiveness of booster immunization with one dose of bivalent oral poliovirus vaccine (bOPV) at 48 months of age after different primary polio immunization schedules. At 48 months of age, one dose of bOPV was administered, and their poliovirus types 1-3 (PV1, PV2, and PV3, respectively)-specific neutralizing antibody levels were determined. Participants found to be negative for any type of PV-specific neutralizing antibody at 24, 36, or 48 months of age were re-vaccinated with inactivated polio vaccine (IPV). The 439 subjects who received a bOPV booster immunization at the age of 48 months had lower PV2-specific antibody levels compared with those who received IPV. One dose of IPV during basic polio immunization induced the lowest PV2-specific antibody levels. On the basis of our findings, to ensure that no less than 70% of the vaccinated have protection efficiency, we recommend the following: if basic immunization was conducted with 1IPV + 2bOPV (especially Sabin strain-based IPV), a booster immunization with IPV is recommended at 36 months of age, whereas if basic immunization was conducted with 2IPV + 1bOPV, a booster immunization with IPV is recommended at 48 months of age. A sequential immunization schedule of 2IPV + 1bOPV + 1IPV can not only maintain high levels of antibody against PV1 and PV3 but also increases immunity to PV2 and induces early intestinal mucosal immunity, with relatively good safety. Thus, this may be the best sequential immunization schedule for polio in countries or regions at high risk for polio.
Collapse
Affiliation(s)
- Zhao Yu-Ping
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Li Jing
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Huang Teng
- GuangXi Province Center for Disease Prevention and Control, Nanning, China
| | - Ying Zhi-Fang
- National Institutes for Food and Drug Control, Beijing, China
| | - Zhao Ting
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Che Yan-Chun
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Zhao Zhi-Mei
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Fu Yu-Ting
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Tao Jun-Hui
- Liujiang District Center for Disease Prevention and Control, Liuzhou, China
| | - Yang Qing-Hai
- Liucheng County Center for Disease Prevention and Control, Liuzhou, China
| | - Wei Ding-Kai
- Rong'an County Center for Disease Prevention and Control, Liuzhou, China
| | - Li Guo-Liang
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Yang Xiao-Lei
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Yi Li
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Chen Hong-Bo
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Wang Jian-Feng
- National Institutes for Food and Drug Control, Beijing, China
| | - Jiang Rui-Ju
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Yu Lei
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Cai Wei
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Yang Wei
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Xie Ming-Xue
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Yin Qiong-Zhou
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Pu Jing
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Shi Li
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Hong Chao
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Deng Yan
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Cai Lu-Kui
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Zhou Jian
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Wen Yu
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Li Hong-Sen
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Huang Wei
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Mo Zhao-Jun
- GuangXi Province Center for Disease Prevention and Control, Nanning, China.
| | - Li Chang-Gui
- National Institutes for Food and Drug Control, Beijing, China.
| | - Li Qi-Han
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China.
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China.
| | - Yang Jing-Si
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China.
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China.
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China.
| |
Collapse
|
4
|
Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months. Int J Infect Dis 2023; 130:20-27. [PMID: 36682682 DOI: 10.1016/j.ijid.2023.01.020] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2022] [Revised: 01/11/2023] [Accepted: 01/13/2023] [Indexed: 01/22/2023] Open
Abstract
OBJECTIVES To evaluate the safety, immunogenicity, and lot-to-lot consistency of Sabin strain-based inactivated polio vaccine (sIPV) in a five-dose vial presentation. METHODS Stage I was an open-label safety observation, in which 72 healthy subjects (including 24 adults, children, and infants each) were given one or three doses of the five-dose vial sIPV; stage II was a randomized, blinded, and positive-control study, in which 1500 infants were randomized at the ratio of 1: 1: 1: 1: 1 into five groups to receive either three doses of the five-dose sIPV three lots, a conventional inactivated poliovirus vaccine, or a single-dose sIPV as controls, for primary immunization. Safety, immunogenicity, and lot-to-lot consistency were assessed. RESULTS Among 1456 subjects who completed the primary immunization, the geometric mean titer ratios of types 1, 2, and 3 of each pair of lots were all within the equivalence criteria margin (0.67-1.50). The seroconversion rates of types 1, 2, and 3 in the combined test group were 98.02%, 94.07%, and 98.77%, respectively, which were noninferior to both control groups. The overall incidence of adverse reactions was 29.68% and erythema was the most common adverse reaction with incidences of 10.47%,9.33%, and 9.73% in the combined test group and control groups (P >0.05). CONCLUSION The five-dose sIPV demonstrated good safety, immunogenicity, and lot-to-lot consistency.
Collapse
|
5
|
Deng Y, Yi L, Li Y, Zhao Z, Zhong Z, Shi H, Li J, Liang Y, Yang J. Safety evaluation on concomitant immunization with inactivated poliomyelitis vaccine produced from Sabin strains and other vaccines (from 2015 to 2020). Hum Vaccin Immunother 2022; 18:2041944. [PMID: 35258415 PMCID: PMC9009915 DOI: 10.1080/21645515.2022.2041944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Objective To evaluate the safety of concomitantly administering inactivated poliomyelitis vaccine produced from Sabin strains (sIPVs) with other vaccines. Methods A descriptive analysis was carried out on adverse events following immunization (AEFI) based on the administration of sIPV alone or concomitant with other vaccines (from 2015 to 2020) using data from the national AEFI surveillance system of China (CNAEFIS). All adverse reactions (ADRs) of the concomitant immunization were coded using a medical dictionary for regulatory activities (MedDRA) before comparison. Results The CNAEFIS reported a total of 9130 sIPV-related AEFI cases, including 6842 AEFI cases collected after immunization with sIPV alone and 2288 AEFI cases collected after immunization of sIPV concomitant with other vaccines. The combination of sIPV with diphtheria, tetanus and pertussis vaccine (DTaP) was correlated with the highest frequency of AEFI, which accounted for 53.50% of all 2288 AEFI cases. After MedDRA-based coding, the most frequent ADR was fever (70.18%), followed by erythema and swelling at the injection site (6.95%), induration at the injection site (3.85%), dermatitis allergy (3.56%) and urticaria (1.55%). A statistically significant difference (P < .001) was found between sIPV immunization and sIPV immunization concomitant with other vaccines for general reactions (95.36% and 93.22%, respectively) and abnormal reactions (4.64% and 6.78%, respectively). Conclusion No new safety signal is found for sIPV administered concomitantly, although its administration with other vaccines may increase the occurrence of abnormal reactions. Vaccine manufacturers should focus on the safety of administering sIPV with DTaP and carry out relevant clinical studies when necessary.
Collapse
Affiliation(s)
- Yan Deng
- Institute of Medical Biology, Chinese Academy of Medical Science, Kunming, Yunnan, China
| | - Li Yi
- Institute of Medical Biology, Chinese Academy of Medical Science, Kunming, Yunnan, China.,NMPA Key Laboratory for Quality Control and Evaluation of Vaccines and Biological Products, Kunming, Yunnan, China
| | - Ying Li
- Institute of Medical Biology, Chinese Academy of Medical Science, Kunming, Yunnan, China
| | - Zhimei Zhao
- Institute of Medical Biology, Chinese Academy of Medical Science, Kunming, Yunnan, China
| | - Zhilei Zhong
- Institute of Medical Biology, Chinese Academy of Medical Science, Kunming, Yunnan, China
| | - Haoyu Shi
- Institute of Medical Biology, Chinese Academy of Medical Science, Kunming, Yunnan, China
| | - Jiarong Li
- Institute of Medical Biology, Chinese Academy of Medical Science, Kunming, Yunnan, China
| | - Yan Liang
- Institute of Medical Biology, Chinese Academy of Medical Science, Kunming, Yunnan, China.,College of Nursing Health Sciences, Yunnan Open University, Kunming, Yunnan, China
| | - Jingsi Yang
- Institute of Medical Biology, Chinese Academy of Medical Science, Kunming, Yunnan, China.,National & Local Joint Engineering Research Center for Biological Products for Viral Infectious Diseases, Kunming, Yunnan, China
| |
Collapse
|
6
|
Ong-Lim AL, Shukarev G, Trinidad-Aseron M, Caparas-Yu D, Greijer A, Duchene M, Scheper G, van Paassen V, Le Gars M, Cahill CP, Schuitemaker H, Douoguih M, Jacquet JM. Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age. Hum Vaccin Immunother 2022; 18:2044255. [PMID: 35344464 PMCID: PMC9196784 DOI: 10.1080/21645515.2022.2044255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
An inactivated poliovirus vaccine candidate using Sabin strains (sIPV) grown on the PER.C6® cell line was assessed in infants after demonstrated immunogenicity and safety in adults. The study recruited 300 infants who were randomized (1:1:1:1) to receive one of 3 dose levels of sIPV or a conventional IPV based on Salk strains (cIPV). Poliovirus-neutralizing antibodies were measured before the first dose and 28 days after the third dose. Reactogenicity was assessed for 7 days and unsolicited adverse events (AEs) for 28 days after each vaccination. Serious AEs (SAEs) were recorded throughout the study. Solicited AEs were mostly mild to moderate. None of the SAEs reported in the study were judged vaccine related, including one fatal SAE due to aspiration of vomitus that occurred 26 days after the third dose of low-dose sIPV. After 3 sIPV vaccinations and across all dose levels, seroconversion (SC) rates were at least 92% against Sabin poliovirus types and at least 80% against Salk types, with a dose-response in neutralizing antibody geometric mean titers (GMTs) observed across the 3 sIPV groups. Compared to cIPV, the 3 sIPV groups displayed similar or higher SC rates and GMTs against the 3 Sabin types but showed a lower response against Salk types 1 and 2; this was most visible for Salk type 1. While the PER.C6® cell line-based sIPV showed an acceptable safety profile and immunogenicity in infants, lower seroprotection against type 1 warrants optimization of dose level and additional clinical evaluation.
Collapse
Affiliation(s)
- Anna Lisa Ong-Lim
- Philippine General Hospital, University of the Philippines Manila, Manila, Philippines
| | | | | | - Delia Caparas-Yu
- De La Salle Medical and Health Sciences Institute, Cavite, Philippines
| | - Astrid Greijer
- Janssen Vaccines & Prevention B.V., Leiden, The Netherlands
| | - Michel Duchene
- Janssen Vaccines & Prevention B.V., Leiden, The Netherlands
| | - Gert Scheper
- Janssen Vaccines & Prevention B.V., Leiden, The Netherlands
| | | | | | - Conor P Cahill
- Janssen Vaccines & Prevention B.V., Leiden, The Netherlands
| | | | | | | |
Collapse
|
7
|
Gao S, Wei M, Chu K, Li J, Zhu F. Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants. Hum Vaccin Immunother 2022; 18:2050106. [PMID: 35394898 PMCID: PMC9196670 DOI: 10.1080/21645515.2022.2050106] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
The presence of maternal poliovirus antibodies may interfere with the immune response to inactivated polio vaccine (IPV), and its influence on the safety of vaccination is not yet understood. A total of 1146 eligible infants were randomly assigned (1:1) to the IPV and Sabin IPV (SIPV) groups to compare and analyze the efficacy of the two vaccines in preventing poliovirus infection. We pooled the SIPV and IPV groups and reclassified them into the maternal poliovirus antibody-positive group (MAPG; ≥1: 8) and the maternal poliovirus antibody-negative group (MANG; <1: 8). We evaluated the impact of maternal poliovirus antibodies by comparing the geometric mean titer (GMT), seroconversion rate, and geometric mean increase (GMI) of types I-III poliovirus neutralizing antibodies post-vaccination, and incidence rates of adverse reactions following vaccination between the MAPG and MANG. Respective seroconversion rates in the MAPG and MANG were 94% and 100%, 79.27% and 100%, and 93.26% and 100% (all serotypes, P < .01) for types I-III poliovirus, respectively. The GMT of all types of poliovirus antibodies in the MAPG (1319.13, 219.91, 764.11, respectively) were significantly lower than those in the MANG (1584.92, 286.73, 899.59, respectively) (P < .05). The GMI in the MAPG was significantly lower than that in the MANG (P < .05). No statistically significant difference in the incidence of local and systemic adverse reactions was observed between the MAPG and MANG. Thus, the presence of maternal poliovirus antibodies does not affect the safety of IPV but can negatively impact the immune responses in infants after IPV vaccination.
Collapse
Affiliation(s)
- Shuyu Gao
- School of Public Health, Southeast University, Nanjing, PR China
| | - Mingwei Wei
- Vaccine Clinical Evaluation Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, PR China
| | - Kai Chu
- Vaccine Clinical Evaluation Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, PR China
| | - Jingxin Li
- Vaccine Clinical Evaluation Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, PR China.,NHC Key laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, PR China
| | - Fengcai Zhu
- School of Public Health, Southeast University, Nanjing, PR China.,Vaccine Clinical Evaluation Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, PR China.,NHC Key laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, PR China
| |
Collapse
|
8
|
Sun X, Xu Y, Tang F, Xiao Y, Wang Z, Wang B, Zhu X, Yang X, Chen H. Immunogenicity and safety of concomitant administration of the chinese inactivated poliovirus vaccine with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in children: A multicenter, randomized, non-inferiority, controlled trial. Front Immunol 2022; 13:905634. [PMID: 35958596 PMCID: PMC9361845 DOI: 10.3389/fimmu.2022.905634] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2022] [Accepted: 06/27/2022] [Indexed: 11/13/2022] Open
Abstract
Key point Considering that vaccination with the sIPV and DTaP overlap at the ages of 3 and 4 months in China, to reduce the burden of treatment on parents and increase vaccination coverage rates, we designed a postmarket clinical study of co-administration. Background The Sabin-strain-based inactivated poliovirus vaccine (sIPV) and the diphtheria-tetanus-acellular pertussis vaccine (DTaP) have been licensed in China for many years. To conduct a clinical study on the safety and immunogenicity of the sIPV when administered concomitantly with the DTaP. Methods The study population was divided into three groups: group 1 was the sIPV+ DTaP concomitant administration group, group 2 was the sIPV inoculation group, and group 3 was the DTaP inoculation group. Blood samples were collected prevaccination and 30 days postvaccination, and serum antibody levels were detected. Results This study showed that the seropositive and seroconversion rates of type 1, 2 and 3 poliovirus in group 1 were higher than those in group 2, with no statistically significant difference after vaccination (P>0.05). Groups 1 and 3 also showed similar responses for all vaccine antigens except anti-FHA (97.65 (94.09-99.36) vs. 100 (97.89-100)). The geometric mean titers (GMTs) for the DTaP and sIPV among the groups were comparable, and the non-inferiority t test result was P<0.001. The number of local adverse events (AEs) reported in group 1 (29.91%) were larger than those in group 2 (12.39%) and group 3 (21.93%), among which the most common was redness. Similarly, the most common systemic AE was fever. All 5 severe AE (SAE) cases were determined by experts to be unrelated to the vaccines during the study. Conclusions The evidence of similar seroconversion and safety with co-administered DTaP and sIPV supports the co-administration supports the introduction of a strategy of simultaneous administration of both vaccines into routine infant immunization, and it could increase vaccination coverage and protect more infants from morbidity and mortality from these related diseases. Clinical Trial Registration https://clinicaltrials.gov/ct2/show/NCT04054882?term=NCT04054882&cntry=CN&draw=2&rank=1, identifier NCT04054882.
Collapse
Affiliation(s)
- Xiang Sun
- Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China
- *Correspondence: Xiang Sun, ; Xiaoming Yang,
| | - Yan Xu
- Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China
| | - Fenyang Tang
- Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China
| | - Yanhui Xiao
- Medical Affairs, China National Biotec Group Company Limited, Beijing, China
| | - Zhiguo Wang
- Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China
| | - Binbing Wang
- Expanded Program on Immunization, Anhui Provincial Center for Disease Control and Prevention, Anhui, China
| | - Xiaoping Zhu
- Expanded Program on Immunization, Sichuan Provincial Center for Disease Control and Prevention, Sichuan, China
| | - Xiaoming Yang
- Medical Affairs, China National Biotec Group Company Limited, Beijing, China
- *Correspondence: Xiang Sun, ; Xiaoming Yang,
| | - Haiping Chen
- Medical Affairs, China National Biotec Group Company Limited, Beijing, China
| |
Collapse
|
9
|
A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China. Vaccines (Basel) 2022; 10:vaccines10020319. [PMID: 35214777 PMCID: PMC8874468 DOI: 10.3390/vaccines10020319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 02/02/2022] [Accepted: 02/09/2022] [Indexed: 02/04/2023] Open
Abstract
Objectives: One dose of Sabin-strains inactivated polio vaccine (IPV) was introduced into the Chinese immunization program on 1 May 2016. This study aimed to evaluate the safety of Sabin-strains IPV and provide a comparison with conventional Salk-strains IPV. Methods: Adverse events following immunization (AEFI) records associated with Sabin-strains IPV and Salk-strains IPV were extracted from the national AEFI surveillance system (NAEFISS) from 1 May 2016 to 31 December 2020. The vaccination information on Sabin-strains IPV and Salk-strains IPV during the same period was obtained from the Zhejiang provincial immunization information system. Reporting rates of AEFI were calculated by age, city, severity of AEFI, categories of AEFI, and reaction categories and were compared between Sabin-strains IPV and Salk-strains IPV. Results: In total, 3,861,758 doses of Sabin-strains IPV and 1,018,604 doses of Salk-strains IPV were administered during the study period. The overall AEFI reporting rate for Sabin-strains IPV (3.96/10,000 doses) was significantly lower than that for Salk-strains IPV (5.03/10,000 doses) due to the reporting rate of the minor vaccine product-related reaction following Sabin-strains IPV was significantly lower than that for Salk-strains IPV (2.76/10,000 doses vs. 3.83/10,000 doses). The most frequently reported symptoms/signs were fever, induration/swelling, and rash/urticaria. The most frequently reported serious AEFI with a causal relationship was febrile convulsion, with the reporting rates of 0.10/10,000 doses for Sabin-strains IPV and 0.08/10,000 doses for Salk-strains IPV. No significant difference was found in the reporting rates of the other serious AEFI between the two types of IPV. Conclusion: Most of the AEFI following Sabin-strains IPV and Salk-strains IPV were mild and common adverse reactions. The reporting rate of serious AEFI was not significantly different between Sabin-strains IPV and Salk-strains IPV. Sabin-strains IPV had a favorable safety profile and could be widely used.
Collapse
|
10
|
Safety, Immunogenicity and Lot-to-Lot Consistency of Sabin-Strain Inactivated Poliovirus Vaccine in 2-Month-Old Infants: A Double-Blind, Randomized Phase III Trial. Vaccines (Basel) 2022; 10:vaccines10020254. [PMID: 35214712 PMCID: PMC8879689 DOI: 10.3390/vaccines10020254] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 01/20/2022] [Accepted: 01/24/2022] [Indexed: 02/04/2023] Open
Abstract
Background: The Sabin-strain-based inactivated poliovirus vaccine (sIPV) plays an important role in poliomyelitis eradication in developing countries. As part of the phase III clinical development program, this study aimed to evaluate the safety, immunogenicity and lot-to-lot consistency of the sIPV in 2-month-old infants. Method: We conducted a phase III, randomized, double-blind, positive-controlled trial in which 1300 healthy infants were randomly assigned to four groups in a 1:1:1:1 ratio to receive one of the three lots of the sIPV or the control IPV at 2, 3 and 4 months of age. Serum samples were collected before the first dose and 30 days after the third dose of vaccination to assess the immunogenicity. Solicited local and systemic reactions were recorded within 7 days and unsolicited adverse events within 30 days after each vaccination. Results: Of the 1300 randomized infants, 1190 infants completed the study and were included in the per-protocol population. The seroconversion rates in the three lots of the sIPV were 95.67%, 97.03% and 95.59%, respectively, for type 1; 94.33%, 93.73% and 92.88%, respectively, for type 2; and 98.67%, 99.67% and 99.32%, respectively, for type 3. The ratios of GMTs for poliovirus types 1, 2 and 3 of each pair of lots were all between 0.67 and 1.50, therefore meeting the predefined immunological equivalence criteria. For the seroconversion rate of poliovirus types 1, 2 and 3, the pooled sIPV group was non-inferior to the IPV group. The incidence of solicited and unsolicited adverse reactions (ARs) was similar in the pooled sIPV lots and the IPV group, and most of them were mild to moderate in severity. Non-vaccine-related serious adverse events (SAEs) were reported. Conclusions: Three consecutive lots of sIPV demonstrated robust and consistent immunogenicity. The safety and tolerability of the sIPV was acceptable and similar to that of the IPV.
Collapse
|
11
|
Westdijk J, Kogelman A, van der Put R, Eksteen Z, Suarez D, Kersten GFA, Metz B, Danial M. Immunochemical and Biophysical Characterization of Inactivated Sabin Poliovirus Products: Insights into Rapid Quality Assessment Tools. J Pharm Sci 2022; 111:1058-1069. [PMID: 35114211 DOI: 10.1016/j.xphs.2022.01.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 01/28/2022] [Accepted: 01/28/2022] [Indexed: 10/19/2022]
Abstract
The aim of this study was to demonstrate the strength of combining immunochemical and biophysical analysis tools for assessing the quality of Sabin inactivated poliovirus vaccine (Sabin-IPV) bulk products. We assessed Sabin-IPV serotypes 1, 2 and 3 from six different manufacturers and evaluated their comparability through biosensor analysis and biophysical characterization methods, including tryptophan fluorescence and asymmetrical flow field-flow fractionation - multi-angle light scattering analysis. These methods enabled us to assess antigenic as well as conformational and structural integrity profiles, respectively. Based on Sabin-IPV samples that were subjected to accelerated storage conditions, we revealed that existing immunochemical methods exhibit remarkably similar trends to the results obtained by the biophysical characterization methods. While the results underpin that the comparability of Sabin-IPV bulk products of different manufacturers is poor, information about their quality can rapidly be obtained by using both immunochemical and biophysical methods. Furthermore, the study highlights that quality assessment of Sabin-IPV can be obtained through biophysical techniques can complement the assessments performed with monoclonal antibodies and suggests that similar techniques could be employed to characterize other enteroviruses.
Collapse
Affiliation(s)
- Janny Westdijk
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands.
| | - Amy Kogelman
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | - Robert van der Put
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | - Zaskia Eksteen
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | - Diego Suarez
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | - Gideon F A Kersten
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands; Leiden Academic Centre for Drug Research, Einsteinweg 55, 2333 CC Leiden, The Netherlands
| | - Bernard Metz
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | - Maarten Danial
- Intravacc BV, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands.
| |
Collapse
|
12
|
Kang G, Tang F, Wang Z, Hu R, Yu J, Gao J. Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China. Hum Vaccin Immunother 2021; 17:2568-2574. [PMID: 33780310 PMCID: PMC8475579 DOI: 10.1080/21645515.2021.1898306] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2020] [Revised: 02/09/2021] [Accepted: 02/26/2021] [Indexed: 10/21/2022] Open
Abstract
One dose of inactivated poliovirus vaccine (IPV) was introduced into the Chinese Expanded Program on Immunization (EPI) in 2016. IPV made from Sabin strains (sIPV) was newly licensed in China and its safety has been concerned. This study aimed to evaluate the safety of sIPV and provide a comparison with conventional IPV made from wild strains (wIPV). We collected all IPV-related AEFI reports in Jiangsu from the Chinese National Adverse Events Following Immunization Information System (CNAEFIS) for 2016-2019. We obtained the administered doses of IPV from the Jiangsu provincial Electronic Immunization Registries System (JSEIRS). The AEFI reporting rates per 100,000 doses of vaccine administered were compared for sIPV and wIPV. A total of 699 sIPV and 908 wIPV AEFI cases were collected by CNAEFIS in Jiangsu during 2016-2019. The overall AEFI reporting rates were 53.02 per 100,000 doses and 41.25 per 100,000 doses for sIPV and wIPV, respectively (P < .001). For both sIPV and wIPV, the AEFIs were mainly classified as common adverse reactions. The reporting rate of common adverse reactions was higher for sIPV than for wIPV (P < .001). The most frequently reported symptoms/signs were fever, persistent crying, injection site erythema/swelling, rash, and injection site induration. Only 1.14% of sIPV-associated and 2.31% of wIPV-associated AEFI cases were diagnosed as serious. No difference in reporting rate was observed for serious AEFIs (P = .272). sIPV has a favorable safety profile, although it exhibits a slightly higher reporting rate of common adverse reactions than wIPV.
Collapse
Affiliation(s)
- Guodong Kang
- Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Fenyang Tang
- Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Zhiguo Wang
- Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Ran Hu
- Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Jing Yu
- Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Jun Gao
- Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| |
Collapse
|
13
|
Chu K, Han W, Jiang D, Jiang Z, Zhu T, Xu W, Hu Y, Zeng G. Cross-neutralization Capacity of Immune Serum from Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization against Multiple Individual Polioviruses. Expert Rev Vaccines 2021; 20:761-767. [PMID: 33861679 DOI: 10.1080/14760584.2021.1919091] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Introduction: Sabin strain inactivated poliovirus vaccine (sIPV) developed by Sinovac Biotech Co., Ltd., has shown good safety and immunogenicity against parental strains among infants in several finished pre-licensure clinical trials.Areas covered: To further study the neutralizing capacity of investigational sIPV immune serum against Sabin, Salk and recently circulating poliovirus strains, neutralization assay against ten individual strains was performed on backup serum collected from 250 infant participants of the finished phase II clinical trial.Expert commentary:: The sIPV can generate good immunogenicity against Sabin, Salk and recently circulating poliovirus strains. Taking into account its lower containment requirements and financial costs compared with the conventional Salk strain inactivated poliovirus vaccine, sIPV is an affordable and practical option for polio eradication.
Collapse
Affiliation(s)
- Kai Chu
- Department of Vaccine Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Weixiao Han
- Clinical Research Department, Sinovac Biotech Co., Ltd., Beijing, China
| | - Deyu Jiang
- Center for Research & Department, Sinovac Biotech Co., Ltd.,Beijing, China
| | - Zhiwei Jiang
- Statistics department, Beijing Key Tech Statistic Technology Co., Ltd, Beijing
| | - Taotao Zhu
- Clinical Research Department,Sinovac Biotech Co., Ltd., Beijing China
| | - Wenbo Xu
- WHO WPRO Regional Reference Measles/Rubella Laboratory, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yuemei Hu
- Department of Vaccine Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Gang Zeng
- Clinical Research Department, Sinovac Biotech Co., Ltd., Beijing, China
| |
Collapse
|
14
|
Wang Y, Xu Q, Jeyaseelan V, Ying Z, Mach O, Sutter R, Wen N, Rodewald L, Li C, Wang J, Yuan H, Yin Z, Feng Z, Xu A, An Z. Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial. THE LANCET REGIONAL HEALTH. WESTERN PACIFIC 2021; 10:100133. [PMID: 34327346 PMCID: PMC8315596 DOI: 10.1016/j.lanwpc.2021.100133] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 02/22/2021] [Accepted: 03/04/2021] [Indexed: 11/24/2022]
Abstract
BACKGROUND We assessed immunogenicity of three-dose and two-dose immunization schedules with a Sabin-strain inactivated poliovirus vaccine (sIPV) produced by one Chinese vaccine manufacturer. METHODS This was an open label, randomized, controlled trial conducted in 16 vaccination clinics in Shandong province. Infants were allocated randomly to either a 3-dose study arm (sIPV administered at 2, 3, and 4 months of age) or a 2-dose arm (sIPV administered at 4 and 8-11 months of age). Poliovirus neutralizing antibodies were measured in sera collected prior to the first sIPV dose and one month after the last dose. FINDINGS We enrolled 560 infants; 536 (95.7%) completed the study. Final seropositivity rates were >98% for all three serotypes in both study arms. There were no statistically significant differences in seropositivity between the 2-dose and the 3-dose schedule. Final median reciprocal titres of polio antibodies were high overall (>1:768 for all serotypes) and statistically significantly higher in 2-dose recipients compared with 3-dose recipients (p < 0.001). INTERPRETATION This study offers evidence that two doses of sIPV administered at 4 and 8-11 months of age and three doses of sIPV administered at 2, 3, and 4 months of age both provide serological protection against poliomyelitis. Median reciprocal titres of polio antibodies were high overall, and were more related to the interval between doses than the number of doses, with the longer interval of the 2-dose schedule producing higher reciprocal titres than the shorter-interval 3-dose schedule. The protection provided by the 3-dose schedule is achieved earlier in life than the protection with the 2-dose schedule. Countries planning to use an IPV-only schedule in the post-eradication era can consider this 2-dose sIPV option as an immunogenic and dose-sparing strategy. FUNDING World Health Organization (from a grant from International PolioPlus Committee, Rotary International, Evanston, IL, USA).
Collapse
Affiliation(s)
- Yamin Wang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Qing Xu
- Shandong Provincial Center for Disease Control and Prevention, Jinan, China
| | - Vishali Jeyaseelan
- Polio Eradication Department, World Health Organization, Geneva, Switzerland
| | - Zhifang Ying
- National Institutes for Food and Drug Control, Beijing, China
| | - Ondrej Mach
- Polio Eradication Department, World Health Organization, Geneva, Switzerland
| | - Roland Sutter
- Polio Eradication Department, World Health Organization, Geneva, Switzerland
| | - Ning Wen
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Changgui Li
- National Institutes for Food and Drug Control, Beijing, China
| | - Jie Wang
- Dezhou prefecture-level Center for Disease Control and Prevention, Dezhou, Shandong, China
| | - Hui Yuan
- Liaocheng prefecture-level Center for Disease Control and Prevention, Liaocheng, Shandong, China
| | - Zundong Yin
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zijian Feng
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Aiqiang Xu
- Shandong Provincial Center for Disease Control and Prevention, Jinan, China
| | - Zhijie An
- Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
15
|
Capeding MR, Gomez-Go GD, Oberdorfer P, Borja-Tabora C, Bravo L, Carlos J, Tangsathapornpong A, Uppala R, Laoprasopwattana K, Yang Y, Han S, Wittawatmongkol O. Safety and immunogenicity of a new inactivated polio vaccine made from Sabin strains: a randomized, double-blind, active-controlled, phase 2/3 seamless study. J Infect Dis 2020; 226:308-318. [PMID: 33351072 PMCID: PMC9400411 DOI: 10.1093/infdis/jiaa770] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2020] [Accepted: 12/20/2020] [Indexed: 12/15/2022] Open
Abstract
Background A new inactivated polio vaccine made from Sabin strains (sIPV) was developed as part of the global polio eradication initiative. Methods This randomized, double-blind, active-controlled, phase 2/3 seamless study was conducted in 2 stages. Healthy infants aged 6 weeks were randomly assigned to receive 3 doses of 1 of 4 study vaccines at 6, 10, and 14 weeks of age (336 received low-, middle-, or high-dose sIPV, or conventional IPV [cIPV] in stage I, and 1086 received lot A, B, or C of the selected sIPV dose, or cIPV in stage II). The primary outcome was the seroconversion rate 4 weeks after the third vaccination. Results In stage I, low-dose sIPV was selected as the optimal dose. In stage II, consistency among the 3 manufacturing lots of sIPV was demonstrated. The seroconversion rates for Sabin and wild strains of the 3 serotypes after the 3-dose primary series were 95.8% to 99.2% in the lot-combined sIPV group and 94.8% to 100% in the cIPV group, proving the noninferiority of sIPV compared to cIPV. No notable safety risks associated with sIPV were observed. Conclusions Low-dose sIPV administered as a 3-dose vaccination was safe and immunogenic compared to cIPV. Clinical Trials Registration NCT03169725.
Collapse
Affiliation(s)
- Maria Rosario Capeding
- Department of Microbiology, Research Institute for Tropical Medicine, Muntinlupa City, Philippines
| | | | - Peninnah Oberdorfer
- Division of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Charissa Borja-Tabora
- Clinical Research Division, Research Institute for Tropical Medicine, Muntinlupa City, Philippines
| | - Lulu Bravo
- Department of Pediatrics, University of the Philippines Manila, Manila, Philippines
| | - Josefina Carlos
- Department of Pediatrics, College of Medicine, University of the East-Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines
| | | | - Rattapon Uppala
- Department of Pediatrics, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand
| | | | - Yunjeong Yang
- Life Sciences, LG Chem, Ltd., Seoul, Republic of Korea
| | - Song Han
- Life Sciences, LG Chem, Ltd., Seoul, Republic of Korea
| | - Orasri Wittawatmongkol
- Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| |
Collapse
|
16
|
Tang R, Li G, Zhang C, Zhi H, Zhu J, Wang J, Liang Q, Hu Y, Li C. A phase Ⅱ, randomized, controlled trial to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine. Hum Vaccin Immunother 2020; 16:2641-2648. [PMID: 32347778 DOI: 10.1080/21645515.2020.1745593] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Abstract
This phase Ⅱ, randomized, controlled trial aimed to evaluate the safety and immunogenicity of a various Sabin IPV preparations. Six hundred infants aged 60 ~ 90 days received one of five different vaccines: low- (group A), medium- (group B) or high-D antigen content (group C) of an experimental Sabin IPV, control Sabin IPV (group D) or control Salk IPV (group E), on a 0-1-2 month schedule. Participants were observed and followed up within 30 days of each dose to assess safety. Serum samples were collected before the first dose and 30 days after the third dose to assess immunogenicity. After three doses, type-1 seroconversion rates of groups A-E were 99.1%, 100.0%, 99.1%, 99.0%, and 93.4%, respectively; type-2 seroconversion rates were 93.5%, 97.1%, 98.1%, 95.1%, and 91.5%, respectively; and type-3 seroconversion rates were 95.4%, 98.1%, 98.1%, 95.1%, and 100.0%, respectively. Only type-1 seroconversion rates differed significantly for group E. The incidences of injection-site redness (A: 21.9%, B: 23.7%, C: 29.4%, D: 16.2%, E: 12.7%), swelling (A: 6.7%, B: 6.8%, C: 5.0%, D: 0.0%, E: 1.7%) and pain (A: 5.0%, B: 6.8%, C: 7.6%, D: 0.0%, E: 0.9%) all were significantly higher for experimental vaccines relative to control groups. No SAEs were detected related to vaccination, and most adverse reactions were mild or moderate in severity. In conclusion, the experimental Sabin IPVs with low-, medium-, and high-D antigen content all revealed good safety and immunogenicity profiles although being more reactogenic than the control vaccines.
Collapse
Affiliation(s)
- Rong Tang
- Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention (Public Health Research Institute of Jiangsu Province) , Jiangsu, China
| | - Guifan Li
- Department of Registration, Beijing Minhai Biotechnology Co. Ltd , Beijing, China
| | - Chengfu Zhang
- Department of Infectious Disease Control and Prevention, Lianshui County Center for Disease Control and Prevention , Lianshui, Jiangsu, China
| | - Hengkui Zhi
- Department of Infectious Disease Control and Prevention, Dafeng County Center for Disease Control and Prevention , Dafeng, Jiangsu, China
| | - Jiahong Zhu
- Department of Infectious Disease Control and Prevention, Lianshui County Center for Disease Control and Prevention , Lianshui, Jiangsu, China
| | - Jianjun Wang
- Department of Infectious Disease Control and Prevention, Dafeng County Center for Disease Control and Prevention , Dafeng, Jiangsu, China
| | - Qi Liang
- Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention (Public Health Research Institute of Jiangsu Province) , Jiangsu, China
| | - Yuemei Hu
- Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention (Public Health Research Institute of Jiangsu Province) , Jiangsu, China
| | - Changgui Li
- Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control , Beijing, China
| |
Collapse
|
17
|
In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine. Vaccines (Basel) 2020; 8:vaccines8040601. [PMID: 33066050 PMCID: PMC7712366 DOI: 10.3390/vaccines8040601] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Accepted: 10/02/2020] [Indexed: 11/25/2022] Open
Abstract
After years of global collaboration; we are steps away from a polio-free world. However, the currently conventional inactivated polio vaccine (cIPV) is suboptimal for the post eradication era. cIPV production cost and biosafety hazards hinder its availability and coverage of the global demands. Production of IPV from the attenuated Sabin strains (sIPV) was an ideal solution and scientists work extensively to perfect a safe, effective and affordable sIPV. This study investigated the ability of hydrogen peroxide (H2O2), ascorbic acid (AA) and epigallocatechin-3-gallate (EGCG) as alternatives for Formaldehyde (HCHO) to inactivate Sabin-polioviruses strains for sIPV production. Sabin-polioviruses vaccine strains were individually treated with AA, EGCG or H2O2 and were compared to HCHO. This was investigated by determination of the inactivation kinetics on HEP2C cells, testing of D-antigen preservation by ELISA and the immune response in Wistar rats of the four vaccine preparations. H2O2, AA and EGCG were able to inactivate polioviruses within 24 h while HCHO required 96 h. Significant high D-antigen levels were observed using AA, EGCG and H2O2 compared to HCHO. Rat sera tested for neutralizing antibodies showed comparable results. These findings support the idea of using these inactivating agents as safe and time- saving alternatives for HCHO to produce sIPV.
Collapse
|
18
|
Sutter RW, Cochi SL. Inactivated Poliovirus Vaccine Supply Shortage: Is There Light at the End of the Tunnel? J Infect Dis 2019; 220:1545-1546. [PMID: 30958545 PMCID: PMC10547123 DOI: 10.1093/infdis/jiy739] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Accepted: 12/21/2018] [Indexed: 10/05/2023] Open
Affiliation(s)
| | - Stephen L. Cochi
- Global Immunization Division, Centers for Disease Control
and Prevention, Atlanta, Georgia
| |
Collapse
|
19
|
Hu Y, Xu K, Han W, Chu K, Jiang D, Wang J, Tian X, Ying Z, Zhang Y, Li C, Zhu F. Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China. Open Forum Infect Dis 2019; 6:ofz380. [PMID: 31660344 PMCID: PMC6786509 DOI: 10.1093/ofid/ofz380] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Accepted: 08/23/2019] [Indexed: 11/16/2022] Open
Abstract
Background A new Sabin strain inactivated poliovirus vaccine (sIPV) proved to be immunogenic and safe in all IPV primary immunization in the previous study, with the corresponding profiles in sequential immunizations unclear. Methods Two clinical trials on the “IPV + 2 bivalent oral polio vaccine (2bOPV)” (Trial A) and “2IPV + bOPV” (Trial B) vaccination were conducted. Both clinical trials were randomized, controlled, double-blinded, noninferiority trials, and wild-strain IPV (wIPV) was adopted as the control vaccine. In each clinical trial, 240 healthy infants were enrolled and randomly assigned to receive sequential vaccinations containing sIPV or wIPV. Immunogenicity and safety were assessed using per-protocol and safety populations, respectively. Results For Trial A, the seroconversion rates in the experimental and control groups were 100% and 99.1%, respectively, against type 1; both 100.0% against type 3. For Trial B, the seroconversion rates in experimental and control groups were 99.2% and 100.0%, respectively, against type 1; both 100% against type 3. No serious adverse events related to vaccines were reported. Conclusions The new sIPV demonstrated an immunogenicity noninferior to that of the wIPV and a good safety profile in sequential vaccination with bOPV. Clinical trial numbers NCT:03822754; NCT:03822767.
Collapse
Affiliation(s)
- Yuemei Hu
- Department of Vaccine Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Kangwei Xu
- Department of Vaccine Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.,Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control, Beijing, China.,Department of Clinical Research, Sinovac Biotech Co., Ltd., Beijing, China.,Center of Research & Development, Sinovac Biotech Co., Ltd., Beijing, China.,Project Management Center, Sinovac Biotech Co., Ltd., Beijing, China.,Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Weixiao Han
- Department of Clinical Research, Sinovac Biotech Co., Ltd., Beijing, China
| | - Kai Chu
- Department of Vaccine Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Deyu Jiang
- Center of Research & Development, Sinovac Biotech Co., Ltd., Beijing, China
| | - Jianfeng Wang
- Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control, Beijing, China
| | - Xiaohui Tian
- Department of Clinical Research, Sinovac Biotech Co., Ltd., Beijing, China
| | - Zhifang Ying
- Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control, Beijing, China
| | - Ying Zhang
- Project Management Center, Sinovac Biotech Co., Ltd., Beijing, China
| | - Changgui Li
- Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control, Beijing, China
| | - Fengcai Zhu
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| |
Collapse
|